Bapineuzumab Trials Results in Mild-to-Moderate Alzheimer’s Disease (New England Journal of Medicine)


Bapineuzumab is an anti-amyloid-beta monoclonal antibody, which had shown promise for the treatment of Alzheimer’s Disease. Two double-blind, randomised, placebo-controlled, phase 3 trials have been conducted, involving 2204 patients with mild-to-moderate Alzheimer’s disease. One trial involved 1121 carriers of the apolipoprotein E (APOE) ε4 allele. The other trial involved 1331 non-carriers.

There were some treatment differences in biomarkers for the APOE ε4 carriers. These trials did not, however, find any significant improvement in clinical outcomes.

Full Text Link


Salloway, S. Sperling, R. [and] Fox, NC. [et al] (2014). Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. New England Journal of Medicine, January 23rd 2014, Vol.370(4), pp.322-33. (Click here to view the PubMed abstract).

About Dementia and Elderly Care News

Dementia and Elderly Care News. Wolverhampton Medical Institute: WMI. (jh)
This entry was posted in For Doctors (mostly), For Researchers (mostly), International, Pharmacological Treatments and tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , . Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.